Ensysce Biosciences, Inc.
ENSCNasdaq
$0.28
↑ +1.9%Jul 17 close · end-of-day
Price
1Y↓ -86.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.9M
Enterprise Value
$1.2M
P/E
—
P/S
0.4
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$4.7M
Net Income (TTM)
—
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-251.4%
Net Margin
—
ROE
—
ROIC
—
Debt / Equity
—
Net Cash
$745,482.00
Return 1Y
-86.9%
Company profile
Ensysce Biosciences, Inc. engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended. release prodrugs of amphetamine for ADHD medication abuse.
- CEO
- D. Lynn Kirkpatrick, PhD
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- California
- Website
- ensysce.com
Earnings
ENSC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$960,999.00↓ -27.2%
Diluted EPS-$0.52↓ -62.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $3.9M | $3.5M | $2.5M | $2.2M | $5.2M | $5.1M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$1.6M | -$19.9M | -$24.2M | -$10.7M | -$6.7M | -$10.2M |
| Net income | $4.3M | — | — | — | — | — |
| Diluted EPS | $0.00 | -$1.48 | -$139.42 | -$70.40 | -$11.45 | -$3.98 |
| Operating cash flow | -$1.2M | -$8.2M | -$17.9M | -$10.8M | -$7.5M | -$7.8M |
| Free cash flow | — | — | — | — | — | -$7.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -41.0% | -562.7% | -959.9% | -480.5% | -129.2% | -202.1% |
| Net margin | 109.7% | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $181,797.00 | $3.4M | $1.3M | $1.3M | $1.4M | $493,104.00 | $1.9M | $960,999.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.0M | $644,746.00 | -$3.6M | -$2.0M | -$1.8M | -$3.7M | -$2.8M | -$3.6M |
| Net income | — | — | — | — | — | — | — | — |
| Diluted EPS | -$3.35 | $1.00 | -$0.89 | -$1.39 | -$0.79 | -$1.29 | -$0.51 | -$0.52 |
| Operating cash flow | -$2.3M | -$1.0M | -$764,090.00 | -$1.7M | -$2.7M | -$1.9M | -$1.5M | -$3.5M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1075.6% | 18.9% | -274.3% | -149.1% | -127.6% | -758.7% | -147.8% | -370.7% |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 14, 2026
- 6d agoEnsysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Developmentinvestorshub.advfn.com
- 6d agoEnsysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grantfinance.yahoo.com
- 6d agoENSC Receives Vital Funding for Drive to Commercializationfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.